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Objective: The aim of this study was to provide evidence regarding the real-life efficacy of 
pregabalin in the treatment of peripheral neuropathic pain (NeP) in Denmark.
Methods: In this prospective, observational, noninterventional study, pregabalin (Lyrica®) 
was prescribed following usual clinical practice. Compared with baseline, the primary study 
end points after 3 months of observation were changes in 1) the average level of pain during 
the past week, 2) the worst level of pain during the past week, and 3) the least level of pain 
during the past week. The Wilcoxon signed-rank test was used to perform paired analyses, and 
a multivariate regression analysis investigated factors driving change in pain.
Results: A total of 86 of the 128 patients included were regarded as efficacy evaluable (those 
completing 3 months of pregabalin treatment). Patients (59 years) were long-time sufferers of 
peripheral NeP, and 38% of them had comorbidities. The majority had previously been treated 
with tricyclic antidepressants or gabapentin. The average dose of pregabalin was 81.5 mg/d at 
baseline and 240 mg/d after 3 months. A clinically and statistically significant improvement of 
2.2 points in the average level of pain intensity was found after 3 months. The higher the pain 
intensity at baseline, the higher was the reduction of the pain score. Positive results were also 
found for pain-related sleep interference, patients’ global impression of change, quality of life, 
and work and productivity impairment. Twenty-one patients reported 28 adverse events.
Conclusion: This real-life study indicates that for some patients (two-thirds), addition of 
pregabalin for peripheral NeP helps to reduce their pain intensity significantly.
Keywords: noninterventional study, pain intensity, usual clinical practice, sleep interference 
and quality of life
Introduction
Peripheral neuropathic pain (NeP) includes pain conditions such as postherpetic 
neuralgia and painful diabetic neuropathy (DNP). The European guidelines for the 
pharmacological treatment of NeP issued by the European Federation of Neurological 
Societies recommend pregabalin (Lyrica®; Pfizer, Inc., New York, NY, USA) as the 
first-line treatment for the most common NeP conditions. Other drugs also recom-
mended as first-line treatment are tricyclic antidepressants (TCA), gabapentin, and 
the serotonin–norepinephrine reuptake inhibitors duloxetine and venlafaxine for DNP.1 
These drugs are also recommended for the treatment of NeP in Denmark. However, 
because the Danish reimbursement policy places pregabalin as a third-line treatment 
option after TCA and gabapentin, pregabalin can be reimbursed only if lack of efficacy 
or tolerability has been documented for first- and second-line treatment drugs.
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Pregabalin has been studied in a large number of ran-
domized, placebo-controlled clinical trials in different NeP 
conditions, including peripheral NeP. These clinical trials 
have shown that pregabalin is effective and that the numbers 
needed to treat with pregabalin are between 3.4 and 4.2 for 
DNP and 3.4 and 5.6 for postherpetic neuralgia.2 Only a 
few studies have investigated the real-life use and efficacy 
of pregabalin in daily clinical practice in a nonrandomized 
clinical trial setting, for example, studies by Anastassiou 
et al,3 Patel et al,4 and Happich et al.5 Evidence from obser-
vational, noninterventional studies in real-life daily practice 
is important when determining whether the effectiveness of 
pregabalin in daily clinical practice is comparable to that 
observed in randomized clinical trials; real-life, noninterven-
tional studies complement the randomi zed clinical trials.
The aim of this study was to provide additional evidence 
regarding the real-life efficacy of pregabalin and to collect data 
about how pregabalin is used for the treatment of peripheral 
NeP in daily practice within primary and secondary care in 
Denmark.
Methods
The study was designed as a prospective, multicenter, obser-
vational, noninterventional study and was conducted in both 
primary and secondary care settings in Denmark. Patients 
had been diagnosed with peripheral NeP by their general 
practitioner (GP) or a specialist and were treated as per usual 
clinical practice. It was beyond the scope of the study to inves-
tigate how the patients had been diagnosed with NeP. When 
a patient, independent of the study and before consideration 
for observation in the study, was prescribed pregabalin for 
the treatment of peripheral NeP, the patient was informed 
about the study by the GP or specialist. The patient had to 
give informed consent before the first dose of pregabalin 
was taken in order to be enrolled in the study by the GP or 
specialist. Pregabalin was prescribed at doses and durations at 
the discretion of the prescribing physicians providing patient 
care, as per usual clinical practice. Being a noninterventional 
study following daily practice, the payment of pregabalin 
followed the Danish rules of national reimbursement. This 
resulted in some patients having pregabalin reimbursed, with 
only a small co-payment to be paid by the patient, while 
other patients paid for the medication fully themselves. 
Reimbursement for pregabalin was not an inclusion/exclu-
sion criterion. The observational period was 3 months during 
which the patients were followed in accordance with regular 
clinical practice. Due to the nature of the study, there were no 
protocol-scheduled study visits to the clinic, only visits due 
to daily clinical practice. At the end of the 3-month observa-
tion period, all patients received a telephone follow-up by the 
prescribing physician, unless they had dropped out before 
the end of the 3-month observation period.
end points
The primary study end points were 1) the average level of pain 
during the past week compared with baseline, 2) the worst 
level of pain during the past week compared with baseline, 
and 3) the least level of pain during the past week compared 
with baseline. “Past week” refers to the week leading up 
to the 3-month telephone follow-up. To evaluate efficacy, 
the primary end points were measured using the numeric 
rating scale (0–10 Numeric Rating Scale-Pain Intensity, 
also referred to as the 11-point Likert scale). This was done 
to measure the pain intensity at each clinic visit, including 
the baseline visit and telephone follow-up at the end of the 
3-month observation period. An improvement in pain for the 
group of at least 2.0 points on the 11-point Likert scale was 
regarded as a clinically relevant and important improvement, 
in accordance with Farrar et al.6 A number of secondary end 
points were also examined. The secondary end point pain-
related sleep interference during the past week compared 
with baseline was measured using the 11-point Likert scale. 
An improvement in this outcome from baseline to end of 
follow-up of 30% or more on the 11-point Likert scale 
measuring pain-related sleep interference was regarded as 
both a clinically meaningful and a sustained response, as is 
the case in other studies.7 The patient’s global impression of 
change (PGIC – 7-point scale) was used to measure the clini-
cal significance of the treatment for the patient. PGIC values 
of 6 and 7, that is, much improved and very much improved, 
indicated that the patient had experienced an actual change 
at follow-up.8 The level of impairment/disability from work 
due to disease was measured using the work productivity 
and activity impairment (WPAI) questionnaire,9,10 which 
has previously been used for patients with NeP and chronic 
pain.11–13 Finally, the patients’ health-related quality of life 
was measured using the standardized and generic EQ-5D 
instrument.14,15 The end points were measured at all clinic 
visits during the 3-month observation period, including the 
baseline visit and the telephone follow-up after 3 months.
Patient selection
All patients enrolled in the study had to meet the usual 
prescribing criteria for pregabalin as per the local pro-
duct information and were entered into the study at the 
prescribing physicians’ discretion. Patients included in 
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the study had to meet the following six inclusion criteria: 
1) aged 18 years or above; 2) diagnosed with peripheral NeP; 
3) had not previously been prescribed pregabalin for the 
treatment of peripheral NeP (“first prescription patients”) 
or were prescribed pregabalin again (“retreatment patients”) 
but had not used pregabalin within the previous 6 months; 
4) had not taken the first dose of the prescribed pregabalin at 
enrollment; 5) able to read and understand Danish and fill in 
patient questionnaires; and 6) signed a dated informed con-
sent document. Exclusion criteria were 1) patients younger 
than 18 years, 2) patients who did not consent to participate, 
and 3) patients who at study inclusion (baseline) had already 
been prescribed pregabalin for the treatment of generalized 
anxiety disorder or epilepsy.
Data recorded
Data were collected and recorded using electronic case 
report forms at the baseline visit and at all subsequent 
visits, including the telephone follow-up. The following 
information was collected: demographic and socioeconomic 
data (age and sex), data regarding the patient’s pain history 
(time with NeP pain condition, etiology, other pain types, 
comorbidities, and pain drug history), treatment (prebaseline 
treatment, pregabalin treatment and dose, postbaseline treat-
ment), treatment end points (pain intensity, pain-related sleep 
inference, WPAI, PGIC, and quality of life), and finally any 
reported adverse events. Standard criteria were applied in the 
study to all observed or volunteered adverse events, regard-
less of suspected causal relationship to pregabalin, which 
were recorded on the adverse event pages of the case report 
form, including criteria for classification as a serious adverse 
event. Data transformation of WPAI and EQ-5D followed the 
official guidelines issued for these instruments.9,10
Study size
The study was designed to have 80% power to show an 
improvement of at least 0.75 points on the 11-point Likert 
pain scale using a 95% confidence level and assuming a 
true improvement of 1.25 points and standard deviation of 
1.91. Using these assumptions, 115 evaluable patients were 
needed. Patients who were evaluable for efficacy were defined 
as patients with data on pregabalin use at baseline and at the 
3-month telephone follow-up.
Statistical analysis
The study is primarily descriptive and exploratory. No hypothe-
ses are presented. Descriptive analyses were performed for 
all socioeconomic data, pain history data, and pregabalin 
treatment data. All primary and secondary end points were 
analyzed for all patients who continued their pregabalin 
treatment throughout the study and had data collected both 
at baseline and at the telephone follow-up after 3 months. 
Last observation carried forward was used; however, no other 
interpretation of missing data was performed.
A clinically relevant and important improvement on the 
11-point Likert pain scale was regarded as an improvement of 
at least 2.0 points, following Farrar et al.6 To determine whether 
improvements were statistically significant, statistical tests and 
confidence intervals (CIs) in the study were performed and 
assessed from a 5% significance level (two-sided).
The Wilcoxon signed-rank test was used to perform paired 
analysis of the data (baseline vs follow-up after 3 months).
The factors that drive the change in pain (least, average, and 
worst) were evaluated using a multivariate regression model 
(proc mixed model using SAS statistical programming – 
normality checked via residual plots). Factors investigated 
were age, pregabalin dose change from baseline, pain 
intensity at baseline, comorbidity (yes/no), pain history 
of .12 months at baseline (yes/no), and concomitant pain 
medication used at baseline (yes/no). For continuous factors 
(age, pregabalin dose, pain intensity), negative estimates 
indicated that higher factors resulted in improvement of pain, 
whereas for binomial factors (yes/no), negative estimates 
indicated that a “yes” resulted in improvement of pain. The 
regression analysis was performed for the group of patients 
who received the 3-month follow-up and were still using 
pregabalin at that time.
Finally, patients who dropped out, were lost to follow-up, 
or discontinued pregabalin were analyzed in a dropout analy-
sis. The patients from this analysis were compared with the 
patients who were fully evaluable, that is, continued their 
pregabalin treatment throughout the study.
Data protection and ethics committee
The study and its data collection were approved by the 
Danish Data Agency. Furthermore, the Danish Medicines 
Agency and the National Committee on Health Research 
Ethics both confirmed that the study was a noninterventional 
observational study. According to the Danish Medicines Act, 
the obligation to apply for authori zation does not apply to 
noninterventional studies; hence, approvals by either of these 
bodies are not required.
Results
From December 2012 to March 2014, a total of 128 patients 
were screened and included in the study by 28 GPs and four 
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Table 1 Patients’ baseline pain characteristics, origin, and comorbidities
Patients evaluable  
for efficacy  
(N=86)
Patients not evaluable  
for efficacy  
(N=42)
All screened and  
included patients  
(N=128)
Time with neuropathic pain, n (%)
3 months 3 (3.5%) 1 (2.4%) 4 (3.1%)
.3–6 months 5 (5.8%) 1 (2.4%) 6 (4.7%)
.6–12 months 12 (14.0%) 4 (9.4%) 16 (12.5%)
.12 months–3 years 23 (26.7%) 11 (26.2%) 34 (26.6%)
.3–5 years 20 (23.3%) 8 (19.0%) 28 (21.9%)
.5–10 years 17 (19.8%) 7 (16.7%) 24 (18.8%)
.10 years 6 (7.0%) 10 (23.8%) 16 (12.5%)
Pain types besides neuropathic, n (%) Nociceptive: 37 (43.0%);  
visceral: 8 (9.3%)
Nociceptive: 20 (47.6%);  
visceral: 2 (4.8%)
Nociceptive: 57 (44.5%); 
visceral: 10 (7.8%)
Concomitant pain conditions, n (%)
Musculoskeletal pain 40 (46.5%) 18 (42.9%) 58 (45.3%)
Persistent postoperative pain 16 (18.6%) 11 (26.2%) 27 (21.1%)
Posttraumatic pain 10 (11.6%) 7 (16.7%) 17 (13.3%)
cancer-related pain 2 (2.3%) 1 (2.4%) 3 (2.3%)
Other 13 (15.1%) 5 (11.9%) 18 (14.1%)
Comorbiditiesa, n (%)
Anxiety 8 (9.3%) 6 (14.3%) 14 (10.9%)
Depression 12 (14.0%) 8 (19.0%) 20 (15.6%)
Pain-related sleep interference 20 (23.3%) 14 (33.3%) 34 (26.6%)
Memory impairment 1 (1.2%) 8 (19.0%) 9 (7.0%)
Concentration difficulties 3 (2.5%) 8 (19.0%) 10 (12.8%)
No comorbidity present 53 (61.6%) 21 (50%) 74 (57.8%)
Note: aDo not sum to 100% due to missing information.
pain specialists (86 and 42 patients, respectively). One hun-
dred of these patients were classified as completers because 
they had at least a full baseline visit and a telephone follow-up 
after 3 months. The remaining 28 patients were classified as 
noncompleters because they were lost to follow-up or had 
dropped out before the end of the 3-month observation period. 
Eighty-six patients were still on pregabalin treatment at the 
time of the telephone follow-up. This population with both a 
pre- and a postobservation was regarded as the patients who 
were evaluable for efficacy. It is this group that is the focus 
of this study of pregabalin.
The mean age of the patients included was 59 years (range 
26–89 years, 95% CI 55.8–63.0), and 61% were females 
(N=52). Table 1 shows the patients’ baseline pain characteri-
stics, including pain treatment prescribed before the initiation 
of treatment with pregabalin (baseline), and comorbidities. 
Data are presented for all screened and enrolled patients 
(N=128), for the group of patients who were evaluable for 
efficacy after 3 months of observation (N=86), and for the 
group of patients who were not evaluable for efficacy due to 
dropping out, lost to follow-up, or discontinued pregabalin 
treatment (N=42).
The table shows that the majority of the patients who 
were evaluable for efficacy had suffered from peripheral 
NeP for quite a long time; nearly 80% had experienced NeP 
for .12 months. More than half of the patients (51%–52%) 
had concomitant nociceptive or visceral pain conditions. 
Many of the patients who were prescribed pregabalin also 
had other concomitant pain conditions in addition to their 
NeP diagnosis, such as musculoskeletal pain, postoperative 
pain, and posttraumatic pain. Around 38% of the patients had 
comorbidities, with pain-related sleep interference being the 
most frequent, followed by depression and anxiety. Despite 
a lower rate of comorbidity, the patients who were evaluable 
for efficacy had similar baseline pain characteristics as all 
screened and included patients.
Due to the Danish reimbursement-driven treatment algo-
rithm, most of the patients had previously been treated with 
TCA (35%), gabapentin (54%), or duloxetine (6%) for their 
peripheral NeP. For 36% of the patients, pregabalin was the 
first drug for the treatment of peripheral NeP.
At initiation, the pregabalin dose varied from 25 mg to 
600 mg; the average dose was 81.5 mg (Table 2).
At the 3-month follow-up, the average dose of pregabalin 
was increased to 241 mg/d (range 25–900 mg), which is 
below the recommended daily defined dose of 300 mg/d.16 
Dose increases were recorded infrequently during the 
3-month observation period because pain was not always 
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Figure 1 Change in pain intensity during the past week – baseline visit compared with the telephone follow-up after 3 months (11-point Likert scalea, N=86).
Notes: a11-point Likert scale from 0 (no pain) to 10 (pain as bad as you can imagine). bP-values from paired Wilcoxon signed-rank test.
Table 2 Pregabalin treatment dosage (N=86)
Mean 
(mg/d)
Median 
(mg/d)
95% Confidence 
interval
At baseline (N=84)a 81.5 50 62.2–100.9
Month 1 (n=64, 76%)b 148.4 75 112.4–184.5
Month 2 (n=48, 57%)b 145.3 100 111.9–178.8
Month 3 (n=48, 57%)b 169.3 125 127.1–211.5
after 3 months (telephone 
follow-up) (n=86, 100%)c
240.7 150 195.6–285.8
Notes: an=84 due to missing dose information for two patients. bDosage 
observations in Month 1, Month 2, and Month 3 were not reported for every patient 
because not all patients visited the clinic every month (no scheduled study visits). 
Therefore, dosage information was reported for Month 1, Month 2, and Month 3 
at different times. cAll 86 patients who were evaluable for efficacy, that is, were on 
pregabalin during the 3 months, were contacted after 3 months from baseline and 
provided information about pregabalin dosage.
the patient’s primary reason for returning to the GP or 
specialist.
At the baseline visit, 96.5% of the patients used pain 
medication for their peripheral NeP. Once treatment with 
pregabalin was initiated, only 77.7% of the patients used 
more than one pain medication. The major reason for this 
drop was that most of the patients who had previously used 
gabapentin stopped using this drug from 23.1%–5.4% after 
initiating use of pregabalin. The remaining group expected 
to finalize treatment with gabapentin soon after initiating the 
treatment with pregabalin. There were also slightly fewer 
patients who received weak opioids from 24.5%–21.4% and 
nonsteroidal anti-inflammatory drugs from 17.5%–14.3% 
after the initiation of pregabalin.
Primary efficacy end point
Figure 1 shows the reduction of experienced peripheral NeP 
(average, worst, and least pain) recorded at the end of the 
3-month observation period compared with baseline (prior 
to initiation of the pregabalin treatment).
Figure 1 shows that the average level of experienced 
pain was reduced by 2.2 points on the 11-point Likert pain 
scale after 3 months of treatment compared with baseline 
levels. The pain intensity was reduced from a baseline score 
of 6.7%–4.5% on the scale (minimum–maximum: 3–10; 
P,0.001). For all three primary end points, the pain reduc-
tion was statistically significant, and for the average and worst 
pain intensity, the results at 3 months also show clinically 
important improvements (changes $2.0).
A multivariate regression analysis was performed to 
determine which factors (age, pregabalin dose at baseline, 
pain intensity at baseline, comorbidity, pain history, and 
concomitant pain medication) drove the change in pain 
intensity during the 3-month observation period. Results 
showed that for all three levels of pain intensity (least, 
average, and worst), a high pain intensity at baseline 
resulted in a significant improvement of the pain condi-
tion. Furthermore, for the worst pain experienced, a pain 
history of  .12 months at baseline resulted in significantly 
(P=0.027) less improved pain. All other factors were 
nonsignificant.
Secondary end points
A number of secondary end points were reported in the study, 
that is, pain-related sleep interference during the past week, 
PGIC, patients’ WPAI, and finally patients’ health-related 
quality of life.
Figure 2 shows the pain-related sleep interference after 
3 months of observation of pregabalin treatment compared 
with baseline.
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Baseline visit 3 months after initiation of pregabalin 
treatment (telephone follow-up)
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Figure 2 Pain-related sleep interference during the past week compared with 
baseline (11-point Likert scalea, N=86).
Notes: a11-point likert scale from 0 (pain did not interfere with sleep) to 10 
(pain completely interfered with sleep). bP-value from paired Wilcoxon signed-
rank test.
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Figure 3 Patients’ global impression of change (PGIC; N=86).
As shown in Figure 2, pain-related sleep interference 
was on average reduced by 3 points (57%) on the scale 
during the 3-month treatment period. This is both clinically 
relevant ($30% improvement from baseline) and statisti-
cally significant. After 3 months, only minor pain-related 
sleep interference was present with a value of 2.3 on the 
Likert scale. Median pain-related sleep interference was 
reduced by 4 points (from 6 points at baseline to 2 points 
after 3 months).
Similar to the primary end point of reduction in pain 
intensity and the reduction in pain-related sleep interfer-
ence, the results of the patient’s own assessment, as recorded 
on the PGIC, showed a clinically significant improve-
ment after 3 months of treatment; 62% (N=53) of the 
participating patients were (very) much improved (Figure 3). 
Furthermore, 30% (N=26) felt minor improvements caused 
by the treatment. Only seven patients did not experience any 
improvement.
The patients’ expressed quality of life also improved 
during the 3-month observation period. The mean quality-
adjusted life year (QALY) for the study patients at baseline 
was 0.47 (EQ-5D). This figure increased to 0.63 after 
3 months of treatment, corresponding to a statistically sig-
nificant 0.16 QALY improvement on the 0–1 QALY scale. 
This result was based on 64 patients who filled out the patient 
questionnaires both at baseline and after 3 months. Similar 
significant improvement was found on the visual analog scale 
of the EQ-5D instrument (0.15).
Because 80% of the patients included in the study were 
not active in the workforce due to retirement (65+ age and 
early retirement due to disability), only 25 (20%) of the 
included patients with pain were working. For these working 
subjects, the number of their working hours affected over 
the past 7 days due to their NeP condition (∼28–30 hours 
on average), as recorded on the WPAI questionnaire, was 
comparable at baseline and after 3 months of treatment. How-
ever, their work productivity was statistically significantly 
improved (P=0.0081) because they were less impaired by 
their NeP condition after 3 months of treatment. Similarly, 
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there was a statistically significant improvement in the ability 
of the patients with NeP to perform regular daily activities 
other than work (P=0.0005), and less hours in general were 
affected due to their pain condition (P=0.001) after 3 months 
of treatment.
adverse events
No serious adverse events were reported. However, 21 (16%) 
of the 128 patients included in the study reported 28 adverse 
events. Of the 28 adverse events, 27 were assessed by the 
investigator to be related to the use of pregabalin. The most 
frequent of these were dizziness (5), sedation (4), nausea (3), 
vertigo (3), and increase in weight (3).
Half of the 28 patients who dropped out of the study 
(N=14) reported adverse events as the reason for their drop-
out. Four patients indicated lack of effect of the pregabalin 
treatment as a reason for their discontinuation. The rest of 
the patients indicated other discontinuation reasons, such as 
a positive effect of treatment with no perceived need to con-
tinue taking medicine, cost of drug, confidentiality concerns, 
and moving to another city.
Patients who were not evaluable  
for efficacy
A total of 42 of the 128 included patients were not evalu-
able for efficacy and were, therefore, not included in the 
analysis. This group of patients had dropped out, was lost 
to follow-up, or had discontinued pregabalin at the 3-month 
telephone follow-up. The average age of the nonevaluable 
group was 57 years, and 74% were females. Compared with 
the 86 patients who were evaluable for efficacy, the average 
age was nearly the same in the two groups, but the percent-
age of females was lower in the group evaluable for efficacy 
(61%). As shown in Table 1, the group of nonevaluable 
patients tended to have a slightly longer history of NeP (86% 
with .12 months), and nearly one-fourth had a history of 
NeP of .10 years as compared with 7% among the efficacy 
evaluable patients. Differences were less pronounced with 
respect to pain type and etiological background between the 
two groups (Table 1). However, a higher share of patients had 
comorbidities among the 42 nonevaluable (50%) than the 86 
evaluable patients (39%); the former reporting more frequent 
pain-related sleep interference, memory impairment, and 
concentration difficulties. The initiating average daily dose 
of pregabalin at the baseline visit was also slightly higher 
for the group of patients who were not evaluable for efficacy 
(93.5 mg, 95% CI 56–131) compared with the 86 patients 
evaluable for efficacy (81.5 mg, 95% CI 62.2–100.9).
Using the method for last observation on pregabalin 
therapy carried forward, change in pain (least, average, and 
worst) was further evaluated among the 28 dropout patients. 
Results were compared with the patients who were evaluable 
for efficacy (N=86). This comparison showed that the magni-
tude of the average change in pain found in the dropout group 
was lower than the average change in pain found among the 
patients who were evaluable for efficacy; the magnitude of 
the pain reduction for the dropout group was less than half 
of that found for patients who were evaluable for efficacy. 
However, this difference was not evaluated statistically due 
to lack of statistical power.
Discussion
The objective of this study was to assess the use and efficacy 
of pregabalin in the treatment of patients with peripheral 
NeP in real-life daily clinical practice. The patient group 
investigated was a difficult-to-treat group of patients with 
the majority having a long (.12 months) history of NeP. 
Moreover, a large proportion of the patients had previously 
been treated with TCA and/or gabapentin.
Registration of pregabalin treatment throughout the 
study showed that dose escalation occurred in the primary 
and secondary care as expected. However, the dosages used 
(average dose of 241 mg/d after 3 months of treatment) were 
generally lower than the recommended daily defined dose of 
300 mg.16 They were also lower than the dosages typically 
used in pregabalin randomized controlled trials, including 
trials where patients were allowed to titrate.17 One explanation 
for the lower average dose of pregabalin in this study is that 
some clinics enrolled many elderly people, primarily women, 
for whom uptitration of the pregabalin dosage started from 
a lower level and only slowly increased. A further argument 
could be that the period of observation was only 3 months, 
whereas a longer observation period, for example, 6 months, 
would have contributed to a higher dosage level of pregabalin. 
However, a previous study with a 6-month observation period 
has not been able to confirm this.5
Use of low doses of pregabalin after a period of treatment 
has also been found in a number of other studies focusing 
on real-life efficacy of pregabalin. Johannessen Landmark 
et al18 called in real-life settings upon individualization of 
pregabalin therapy and doses regardless of treatment indi-
cation. In Anastassiou et al,3 the most common dose was 
150 mg/d at the last follow-up after 62 days. In Happich 
et al,5 the mean daily dosage over a 6-month treatment period 
with pregabalin was reported as low as 53.9 mg/d, and in a 
study by Blanco Tarrio et al,19 the average dose per day of 
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1,670 patients treated with pregabalin was 202 mg/d. Similar 
low dosages down to 125 mg/d have been found in market 
research studies of pregabalin. In comparison to these studies, 
the average dosage of 241 mg/d after 3 months of pregaba-
lin treatment in this study is neither low nor unusual. Yang 
et al20 reported poor patient compliance due to low treatment 
dosage levels. However, this did not seem to have been the 
case in the present study, and we claim that, in contrast, too 
high dosage levels may lead to poor patient compliance as 
a consequence of early undesired side effects. Twenty-eight 
patients did drop out of the study, and half of them due to 
adverse events. Given that it is difficult to treat a group of 
patients who have tried other pharmacological treatments 
without adequate success before, this dropout rate is not 
regarded as being high.
The patients included in this study did experience a sig-
nificant and clinically relevant improvement in their average 
level of pain intensity, with a reduction of 2 points on the 
11-point Likert pain scale following 3 months of treatment 
with pregabalin. The results of the secondary end points 
support the effectiveness of pregabalin in the treatment of 
peripheral NeP. A significant and clinically relevant improve-
ment was found with respect to pain-related sleep interference 
and the patients’ subjective assessment of pain as measured 
by the PGIC questionnaire. After the pain-treatment period of 
3 months, the work productivity was significantly improved 
for the subset of patients who were still in the workforce. 
Furthermore, quality of life of the patients was also signifi-
cantly improved.
Similar results were obtained in a noninterventional, 
multicenter, postmarketing study conducted in Greece and 
published in 2011.3 This study, however, showed a lower 
effect size in pain reduction than the study conducted in 
Greece.
Study limitations
The study was a prospective, multicenter, observational, 
noninterventional drug study. The main limitation of this 
noninterventional study was within its study design. The 
open-label nature of the design of this study imposes limi-
tations on the conclusion that can be drawn concerning the 
efficacy and tolerability of pregabalin. These include a lack 
of placebo-treated control patients and the fact that patients 
and prescribing physicians were not blinded to treatment. 
Because of these limitations, the efficacy and safety profile 
of pregabalin may be influenced by both the patients and the 
prescribing physician’s expectations. This, coupled with the 
absence of a placebo-control group, may make it difficult to 
firmly and confidently conclude that pregabalin is effective 
in real-life clinical practice.
The statistical analysis was performed without adjustment 
for multiplicity of the three pain end points. However, the 
P-value of the primary end point, as well as the P-values of 
the other two pain measures, was low and would also have 
been statistically significant when adjustment for multiplicity 
in the three pain end points was applied, using the Bonferroni 
correction method.
Eighty-six patients of the 115 patients needed, as defined 
by the sample size calculations, completed the study. This 
may call for a careful interpretation of the results as the 
patients completing the 3 months of pregabalin treat-
ment were from a selected patient population who had 
responded to or tolerated the treatment with pregaba-
lin. However, when comparing the baseline data for the 
86 patients who were evaluable for efficacy with the data 
for the 42 patients who were not evaluable for efficacy, no 
large differences were found. The comparison did, however, 
imply that the 42 patients who were not evaluable for effi-
cacy had a longer history of  NeP and were more diseased 
in terms of comorbidities; both of these conditions cannot 
be excluded as reasons for dropout or lost to follow-up. 
The proportion of patients using concomitant pain medi-
cation decreased in this study, following the initiation of 
pregabalin treatment.
Another limitation could be the lack of consistent evalua-
tion or diagnosis criteria across the patient cohort in the study 
because the patients were diagnosed and followed up using 
the individual GP or specialist practice’s criteria. This is a 
consequence and potential weakness of a noninterventional 
study following daily clinical practice.
Despite the limitations in the study design, the study has 
a high external validity, that is, it shows the efficacy of pain 
treatment in clinical practice in a group of difficult-to-treat 
patients who have received pregabalin for a 3-month period. 
The external validity is probably higher than in randomized 
controlled trial studies with strict inclusion and exclusion 
criteria and criteria for study conduct.
Comparing with other studies in the 
literature
Similar to other studies in the literature, this study found 
improvement in the pain intensity following initiation of 
pregabalin treatment for peripheral NeP. Anastassiou et al3 
assessed the impact of pregabalin for the treatment of NeP 
under real-life conditions and concluded that pregabalin led 
to significant 4-point reductions in pain (4.16 on a 11-point 
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numerical rating scale) and in pain-related sleep interfer-
ence. Patel et al4 and Happich et al5 evaluated the real-life 
efficacy of pregabalin for the treatment of diabetic peripheral 
neuropathy and found similar reductions in the mean pain 
intensity, pain-related sleep, and PGIC. Focusing on pain-
related sleep interferences in patients with spinal cord injury 
and NeP, Cardenas et al7 demonstrated a significant improve-
ment of sleep quality following pregabalin treatment. In 
terms of tolerability, the 78% pregabalin continuation rate 
at the end of study found in this study is comparable to the 
76% found in the study by Anastassiou et al.3 Discontinu-
ation due to lack of efficacy occurred in 3% of the patients 
in this study compared with 0.7% in Anastassiou et al.3 The 
explanation for this may be that the group of patients in this 
study was a harder-to-treat group of patients with a long 
history of peripheral NeP and use of pain-related medicine. 
Finally, the number of adverse events found in this study 
was not high. As an example, more than half of the patients 
(54%) experienced all-cause adverse events in the study by 
Anastassiou et al,3 whereas this was the case only for 22% 
in this study.
Conclusion
Although the recruitment target was not met, this study of 
real-life pain management in Denmark indicates a positive 
effect in terms of pain relief on those patients with peripheral 
NeP completing 3 months of pregabalin treatment (86 of 
128 included). The addition of pregabalin treatment helps 
to significantly reduce pain intensity and improve well-
being in these patients with difficult-to-treat peripheral NeP 
who had tried many types of treatment, for example, with 
TCA and/or gabapentin (67%), without satisfactory pain 
relief. The higher pain intensity the patient had at baseline, 
the higher was the reduction in the pain score experienced 
by the patient after 3 months of treatment. Fewer patients 
used other concomitant pain medications when treatment 
with pregabalin was initiated. Patients not completing the 
3 months of pregabalin medication had typically a longer 
history of NeP, more frequently had comorbidities, and had 
higher individual doses of pregabalin (faster titration). This 
study protocol based on daily practice may prove to be useful 
as a platform for individual patient treatment with regard to 
titration of pregabalin dosage. The tolerability of pregabalin 
treatment seems to be comparable to that found in other 
studies, with similar rates of discontinuation. Therefore, the 
positive benefit from pregabalin in the treatment of NeP as 
shown in the randomized clinical trials is confirmed in this 
real-life study.
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